Abstract
Systemic administration of CCK-8S (1 or 10 micrograms/kg IP) markedly inhibited L-dopa-induced dyskinesias in parkinsonian monkeys, but did not interfere with locomotor stimulation by L-dopa. CCK analogues may be useful antidyskinetic agents for improved control of Parkinson's disease.
MeSH terms
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Animals
-
Disease Models, Animal
-
Dyskinesia, Drug-Induced / prevention & control*
-
Levodopa / therapeutic use
-
Levodopa / toxicity*
-
Parkinson Disease, Secondary / drug therapy*
-
Saimiri
-
Sincalide / therapeutic use*
Substances
-
Levodopa
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
Sincalide